Details of the Drug

General Information of Drug (ID: DM3GTAL)

Drug Name

Maribavir

Synonyms

176161-24-3; Benzimidavir; (2S,3S,4R,5S)-2-(5,6-dichloro-2-(isopropylamino)-1H-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; 1263W94; UNII-PTB4X93HE1; PTB4X93HE1; 5,6-Dichloro-2-(isopropylamino)-1-(beta-L-ribofuranosyl)-1H-benzimidazole; 5,6-Dichloro-N-(1-methylethyl)-1-beta-L-ribofuranosyl-1H-benzimidazol-2-amine; (2S,3S,4R,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol; Maribavir [USAN:INN:BAN]; Camvia; C15H19Cl2N3O4; Camvia(TM); Camvia (TN); Bzurea

Indication

Disease Entry	ICD 11	Status	REF
Cytomegalovirus infection	1D82	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

376.2

Logarithm of the Partition Coefficient (xlogp)

2.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 17.2 mg/L [2]
Clearance: The apparent oral clearance of drug is 2.85 L/h [2]
Elimination: Following the oral administration of radiolabeled maribavir, 61% of the dose was excreted in the urine (<2% as unchanged drug) and 14% was excreted in the feces (5.7% as unchanged drug) [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 4.32 hours [2]
Metabolism: The drug is metabolized via the CYP3A4 and [2]
Vd: The volume of distribution (Vd) of drug is 27.3 L [2]

Chemical Identifiers

Formula: C15H19Cl2N3O4
IUPAC Name: (2S,3S,4R,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol
Canonical SMILES: CC(C)NC1=NC2=CC(=C(C=C2N1[C@@H]3[C@H]([C@H]([C@@H](O3)CO)O)O)Cl)Cl
InChI: InChI=1S/C15H19Cl2N3O4/c1-6(2)18-15-19-9-3-7(16)8(17)4-10(9)20(15)14-13(23)12(22)11(5-21)24-14/h3-4,6,11-14,21-23H,5H2,1-2H3,(H,18,19)/t11-,12-,13-,14-/m0/s1
InChIKey: KJFBVJALEQWJBS-XUXIUFHCSA-N

Cross-matching ID

PubChem CID: 471161
CAS Number: 176161-24-3
DrugBank ID: DB06234
TTD ID: D07WXI
INTEDE ID: DR1896

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytomegalovirus Ganciclovir kinase (CMV UL97)	TTXQ04B	UL97_HCMVA	Inhibitor	[3]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215596.
2	FDA Approved Drug Products: Livtencity (maribavir) tablets for oral use
3	The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol. 2003 Jan;77(2):905-14.
4	Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother. 2006 Apr;50(4):1130-5.